Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-10-2013 | Review

MicroRNAs targeting EGFR signalling pathway in colorectal cancer

Authors: Jitka Mlcochova, Petra Faltejskova, Radim Nemecek, Marek Svoboda, Ondrej Slaby

Published in: Journal of Cancer Research and Clinical Oncology | Issue 10/2013

Abstract

MicroRNAs (miRNAs) are short, 18–25-nucleotide long, non-coding single-stranded RNAs, which are capable to regulate gene expression on post-transcriptional level through binding to their target protein-encoding mRNAs. miRNAs regulate individual components of multiple oncogenic pathways. One of them is epidermal growth factor receptor (EGFR) signalling pathway that regulates cell proliferation, differentiation, migration, angiogenesis and apoptosis. All these processes are deregulated in colorectal cancer (CRC). Moreover, EGFR has been validated as the therapeutic target in CRC, and monoclonal antibodies cetuximab and panitumumab are used in the therapy of patients with metastatic CRC. Because of the extensive involvement of miRNAs in the regulation of EGFR signalling, it seems they could also serve as promising predictive biomarkers to anti-EGFR therapy. In this review, we summarize current knowledge about miRNAs targeting EGFR signalling pathway, their functioning in CRC pathogenesis and potential usage as biomarkers.

Akao Y, Nakagawa Y, Naoe T (2006) MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep 16:845–850PubMed

Allgayer H (2010) Pdcd4, a colon cancer prognostic that is regulated by a microRNA. Crit Rev Oncol Hematol 73:185–191. doi:10.1016/j.critrevonc.2009.09.001 PubMedCrossRef

Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634. doi:10.1200/JCO.2007.14.7116 PubMedCrossRef

Arcaroli JJ, Quackenbush KS, Powell RW et al (2012) Common PIK3CA mutants and a novel 3′ UTR mutation are associated with increased sensitivity to saracatinib. Clin Cancer Res 18:2704–2714. doi:10.1158/1078-0432.CCR-11-3167 PubMedCrossRef

Bakirtzi K, Hatziapostolou M, Karagiannides I et al (2011) Neurotensin signaling activates microRNAs-21 and -155 and Akt, promotes tumor growth in mice, and is increased in human colon tumors. Gastroenterology 141(1749–1761):e1. doi:10.1053/j.gastro.2011.07.038

Barault L, Veyrie N, Jooste V et al (2008) Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 122:2255–2259. doi:10.1002/ijc.23388 PubMedCrossRef

Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67:2643–2648. doi:10.1158/0008-5472.CAN-06-4158 PubMedCrossRef

Borralho PM, Kren BT, Castro RE et al (2009) MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells. FEBS J 276:6689–6700. doi:10.1111/j.1742-4658.2009.07383.x PubMedCrossRef

Chen X, Guo X, Zhang H et al (2009) Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 28:1385–1392. doi:10.1038/onc.2008.474 PubMedCrossRef

Chiang Y, Song Y, Wang Z et al (2011) Aberrant expression of miR-203 and its clinical significance in gastric and colorectal cancers. J Gastrointest Surg 15:63–70. doi:10.1007/s11605-010-1367-8 PubMedCrossRef

Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358:1160–1174. doi:10.1056/NEJMra0707704 PubMedCrossRef

De Roock W, De Vriendt V, Normanno N et al (2011) KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 12:594–603. doi:10.1016/S1470-2045(10)70209-6 PubMedCrossRef

Di Nicolantonio F, Martini M, Molinari F et al (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705–5712. doi:10.1200/JCO.2008.18.0786 PubMedCrossRef

Diosdado B, van de Wiel MA, Terhaar Sive Droste JS et al (2009) MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression. Br J Cancer 101:707–714. doi:10.1038/sj.bjc.6605037 PubMedCrossRef

Dobashi Y, Watanabe Y, Miwa C et al (2011) Mammalian target of rapamycin: a central node of complex signaling cascades. Int J Clin Exp Pathol 4:476–495PubMed

Earle JSL, Luthra R, Romans A et al (2010) Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. J Mol Diagn 12:433–440. doi:10.2353/jmoldx.2010.090154 PubMedCrossRef

Ferlay J, Shin H-R, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917. doi:10.1002/ijc.25516 PubMedCrossRef

Gao J-S, Zhang Y, Tang X et al (2011) The Evi1, microRNA-143, K-Ras axis in colon cancer. FEBS Lett 585:693–699. doi:10.1016/j.febslet.2011.01.033 PubMedCrossRef

Greer EL, Brunet A (2005) FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24:7410–7425. doi:10.1038/sj.onc.1209086 PubMedCrossRef

Gregersen LH, Jacobsen AB, Frankel LB et al (2010) MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS ONE 5:e8836. doi:10.1371/journal.pone.0008836 PubMedCrossRef

Guo C, Sah JF, Beard L et al (2008) The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer 47:939–946. doi:10.1002/gcc.20596 PubMedCrossRef

Humphreys KJ, Cobiac L, Le Leu RK et al (2013) Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. Mol Carcinog 52:459–474. doi:10.1002/mc.21879 PubMedCrossRef

Iwaya T, Yokobori T, Nishida N et al (2012) Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway. Carcinogenesis 33:2391–2397. doi:10.1093/carcin/bgs288 PubMedCrossRef

Jahid S, Sun J, Edwards RA et al (2012) miR-23a promotes the transition from indolent to invasive colorectal cancer. Cancer Discov 2:540–553. doi:10.1158/2159-8290.CD-11-0267 PubMedCrossRef

Kent OA, Fox-Talbot K, Halushka MK (2012) RREB1 repressed miR-143/145 modulates KRAS signaling through downregulation of multiple targets. Oncogene. doi:10.1038/onc.2012.266 PubMed

Kern HB, Niemeyer BF, Parrish JK et al (2012) Control of MicroRNA-21 expression in colorectal cancer cells by oncogenic epidermal growth factor/Ras signaling and Ets transcription factors. DNA Cell Biol 31:1403–1411. doi:10.1089/dna.2011.1469 PubMedCrossRef

Kim HS, Lee M-S (2007) STAT1 as a key modulator of cell death. Cell Signal 19:454–465. doi:10.1016/j.cellsig.2006.09.003 PubMedCrossRef

Kim NH, Kim HS, Kim N-G, et al. (2011) p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci Signal 4:ra71. doi:10.1126/scisignal.2001744

Langlois M-J, Bergeron S, Bernatchez G et al (2010) The PTEN phosphatase controls intestinal epithelial cell polarity and barrier function: role in colorectal cancer progression. PLoS ONE 5:e15742. doi:10.1371/journal.pone.0015742 PubMedCrossRef

Li J, Chen Y, Zhao J et al (2011a) miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression. Cancer Lett 304:52–59. doi:10.1016/j.canlet.2011.02.003 PubMedCrossRef

Li J, Zhang Y, Zhao J et al (2011b) Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells. Mol Cell Biochem 357:31–38. doi:10.1007/s11010-011-0872-8 PubMedCrossRef

Liu X, Zhang Z, Sun L et al (2011) MicroRNA-499-5p promotes cellular invasion and tumor metastasis in colorectal cancer by targeting FOXO4 and PDCD4. Carcinogenesis 32:1798–1805. doi:10.1093/carcin/bgr213 PubMedCrossRef

Lu Z, Liu M, Stribinskis V et al (2008) MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 27:4373–4379. doi:10.1038/onc.2008.72 PubMedCrossRef

Motoyama K, Inoue H, Takatsuno Y et al (2009) Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol 34:1069–1075PubMed

Nakajima G, Hayashi K, Xi Y et al (2006) Non-coding MicroRNAs hsa-let-7 g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer. Cancer Genomics Proteomics 3:317–324PubMed

Nishida N, Yokobori T, Mimori K et al (2011) MicroRNA miR-125b is a prognostic marker in human colorectal cancer. Int J Oncol 38:1437–1443. doi:10.3892/ijo.2011.969 PubMedCrossRef

Nishimura J, Handa R, Yamamoto H et al (2012) microRNA-181a is associated with poor prognosis of colorectal cancer. Oncol Rep 28:2221–2226. doi:10.3892/or.2012.2059 PubMed

Oda K, Matsuoka Y, Funahashi A, Kitano H (2005) A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol. doi:10.1038/msb4100014 PubMed

Oikawa T, Yamada T (2003) Molecular biology of the Ets family of transcription factors. Gene 303:11–34PubMedCrossRef

Ota T, Doi K, Fujimoto T et al (2012) KRAS up-regulates the expression of miR-181a, miR-200c and miR-210 in a three-dimensional-specific manner in DLD-1 colorectal cancer cells. Anticancer Res 32:2271–2275PubMed

Pagliuca A, Valvo C, Fabrizi E et al (2012) Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene. doi:10.1038/onc.2012.495

Pekow JR, Dougherty U, Mustafi R et al (2012) miR-143 and miR-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes. Inflamm Bowel Dis 18:94–100. doi:10.1002/ibd.21742 PubMedCrossRef

Pichler M, Winter E, Stotz M et al (2012) Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer. Br J Cancer 106:1826–1832. doi:10.1038/bjc.2012.175 PubMedCrossRef

Pritchard CC, Grady WM (2011) Colorectal cancer molecular biology moves into clinical practice. Gut 60:116–129. doi:10.1136/gut.2009.206250 PubMedCrossRef

Pu X, Huang G, Guo H et al (2010) Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol 25:1674–1680. doi:10.1111/j.1440-1746.2010.06417.x PubMedCrossRef

Roskoski R Jr (2012) ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res 66:105–143. doi:10.1016/j.phrs.2012.04.005 PubMedCrossRef

Rossi L, Bonmassar E, Faraoni I (2007) Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro. Pharmacol Res 56:248–253. doi:10.1016/j.phrs.2007.07.001 PubMedCrossRef

Roy HK, Olusola BF, Clemens DL et al (2002) AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 23:201–205PubMedCrossRef

Sachdeva M, Zhu S, Wu F et al (2009) p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 106:3207–3212. doi:10.1073/pnas.0808042106 PubMedCrossRef

Schetter AJ, Leung SY, Sohn JJ et al (2008) MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299:425–436. doi:10.1001/jama.299.4.425 PubMedCrossRef

Schubbert S, Shannon K, Bollag G (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7:295–308. doi:10.1038/nrc2109 PubMedCrossRef

Sebio A, Paré L, Páez D et al (2013) The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3′-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients. Pharmacogenet Genomics 23:142–147. doi:10.1097/FPC.0b013e32835d9b0b PubMedCrossRef

Smits KM, Paranjape T, Nallur S et al (2011) A let-7 microRNA SNP in the KRAS 3′UTR is prognostic in early-stage colorectal cancer. Clin Cancer Res 17:7723–7731. doi:10.1158/1078-0432.CCR-11-0990 PubMedCrossRef

Sood A, McClain D, Maitra R et al (2012) PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Clin Colorectal Cancer 11:143–150. doi:10.1016/j.clcc.2011.12.001 PubMedCrossRef

Sureban SM, May R, Ramalingam S, et al (2009) Selective blockade of DCAMKL-1 results in tumor growth arrest by a Let-7a MicroRNA-dependent mechanism. Gastroenterology 137:649–659, 659.e1–659.e2. doi:10.1053/j.gastro.2009.05.004

Tsang WP, Kwok TT (2009) The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis 30:953–959. doi:10.1093/carcin/bgp094 PubMedCrossRef

Vecchione L, Jacobs B, Normanno N et al (2011) EGFR-targeted therapy. Exp Cell Res 317:2765–2771. doi:10.1016/j.yexcr.2011.08.021 PubMedCrossRef

Vickers MM, Bar J, Gorn-Hondermann I et al (2012) Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease. Clin Exp Metastasis 29:123–132. doi:10.1007/s10585-011-9435-3 PubMedCrossRef

Wienholds E, Plasterk RHA (2005) MicroRNA function in animal development. FEBS Lett 579:5911–5922. doi:10.1016/j.febslet.2005.07.070 PubMedCrossRef

Wu J, Qian J, Li C et al (2010) miR-129 regulates cell proliferation by downregulating Cdk6 expression. Cell Cycle Georget Tex 9:1809–1818CrossRef

Wu L, Li H, Jia CY et al (2012) MicroRNA-223 regulates FOXO1 expression and cell proliferation. FEBS Lett 586:1038–1043. doi:10.1016/j.febslet.2012.02.050 PubMedCrossRef

Wu W, Yang J, Feng X et al (2013) MicroRNA-32 (miR-32) regulates phosphatase and tensin homologue (PTEN) expression and promotes growth, migration, and invasion in colorectal carcinoma cells. Mol Cancer 12:30. doi:10.1186/1476-4598-12-30 PubMedCrossRef

Xi Y, Formentini A, Chien M et al (2006) Prognostic Values of microRNAs in Colorectal Cancer. Biomark Insights 2:113–121PubMed

Xiong B, Cheng Y, Ma L, Zhang C (2013) MiR-21 regulates biological behavior through the PTEN/PI-3K/Akt signaling pathway in human colorectal cancer cells. Int J Oncol 42:219–228. doi:10.3892/ijo.2012.1707 PubMed

Yantiss RK, Goodarzi M, Zhou XK et al (2009) Clinical, pathologic, and molecular features of early-onset colorectal carcinoma. Am J Surg Pathol 33:572–582. doi:10.1097/PAS.0b013e31818afd6b PubMedCrossRef

Yu Y, Sarkar FH, Majumdar APN (2013) Down-regulation of miR-21 induces differentiation of chemoresistant colon cancer cells and enhances susceptibility to therapeutic regimens. Transl Oncol 6:180–186PubMed

Zhang J, Guo H, Zhang H et al (2011) Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1 gene. Cancer 117:86–95. doi:10.1002/cncr.25522 PubMedCrossRef

Zhang G, Xia S, Tian H et al (2012) Clinical significance of miR-22 expression in patients with colorectal cancer. Med Oncol Northwood Lond Engl 29:3108–3112. doi:10.1007/s12032-012-0233-9 CrossRef

Zhong M, Bian Z, Wu Z (2013) miR-30a suppresses cell migration and invasion through downregulation of PIK3CD in colorectal carcinoma. Cell Physiol Biochem 31:209–218. doi:10.1159/000343362 PubMedCrossRef

Zhu H, Dougherty U, Robinson V et al (2011) EGFR signals downregulate tumor suppressors miR-143 and miR-145 in Western diet-promoted murine colon cancer: role of G1 regulators. Mol Cancer Res Mcr 9:960–975. doi:10.1158/1541-7786.MCR-10-0531 CrossRef

Title: MicroRNAs targeting EGFR signalling pathway in colorectal cancer
Authors: Jitka Mlcochova
Petra Faltejskova
Radim Nemecek
Marek Svoboda
Ondrej Slaby
Publication date: 01-10-2013
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 10/2013
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-013-1470-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2013

Prognostic relevance of ubiquitin C-terminal hydrolase L1 (UCH-L1) mRNA and protein expression in breast cancer patients

Rituximab, Ara-C, dexamethasone and oxaliplatin (R-ADOx) is effective for treatment of elderly patients with relapsed mantle cell lymphoma

Doxorubicin induces atypical NF-κB activation through c-Abl kinase activity in breast cancer cells

Expression of E-cadherin, Twist, and p53 and their prognostic value in patients with oral squamous cell carcinoma

The efficacy of nonestrogenic therapy to hot flashes in cancer patients under hormone manipulation therapy: a systematic review and meta-analysis

The prognostic significance of Jun transcription factors in ovarian cancer

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage